Related Experiment Video
Updated: May 11, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro
Cui-yan Han1, Li-ling Yue, Ling-yu Tai
1School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
Abstract:
The epidermal growth factor receptor (EGFR) serves an important function in the proliferation of tumors in humans and is an effective target for the treatment of cancer. In this paper, we studied the targeting characteristics of small peptides (AEYLR, EYINQ, and PDYQQD) that were derived from three major autophosphorylation sites of the EGFR C-terminus domain in vitro. These small peptides were labeled with fluorescein isothiocyanate (FITC) and used the peptide LARLLT as a positive control, which bound to putative EGFR selected from a virtual peptide library by computer-aided design, and the independent peptide RALEL as a negative control. Analyses with flow cytometry and an internalization assay using NCI-H1299 and K562 with high EGFR and no EGFR expression, respectively, indicated that FITC-AEYLR had high EGFR targeting activity. Biotin-AEYLR that was specifically bound to human EGFR proteins demonstrated a high affinity for human non-small-cell lung tumors. We found that AEYLR peptide-conjugated, nanostructured lipid carriers enhanced specific cellular uptake in vitro during a process that was apparently mediated by tumor cells with high-expression EGFR. Analysis of the MTT assay indicated that the AEYLR peptide did not significantly stimulate or inhibit the growth activity of the cells. These findings suggest that, when mediated by EGFR, AEYLR may be a potentially safe and efficient delivery ligand for targeted chemotherapy, radiotherapy, and gene therapy.
Insights
Researchers identified the AEYLR peptide as a promising ligand for targeting epidermal growth factor receptor (EGFR) in cancer. This peptide shows high affinity for EGFR, enhancing drug delivery to tumors without affecting cell growth, suggesting its potential in cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Epidermal growth factor receptor (EGFR) is crucial for human tumor proliferation and a key target in cancer therapy.
- Targeted delivery of therapeutic agents to tumors remains a significant challenge in oncology.
Purpose of the Study:
- To investigate the targeting potential of small peptides derived from EGFR C-terminus autophosphorylation sites.
- To evaluate the efficacy of the AEYLR peptide as a ligand for targeted drug delivery in EGFR-expressing tumors.
Main Methods:
- Synthesis and labeling of peptides (AEYLR, EYINQ, PDYQQD) with FITC for in vitro studies.
- Flow cytometry and internalization assays using EGFR-high (NCI-H1299) and EGFR-null (K562) cell lines.
- Biotinylation of AEYLR to assess binding affinity to human EGFR and non-small-cell lung tumors.
- Conjugation of AEYLR peptide to nanostructured lipid carriers for cellular uptake studies.
- MTT assays to evaluate the effect of AEYLR peptide on cell growth.
Main Results:
- FITC-labeled AEYLR peptide demonstrated significant EGFR targeting activity.
- Biotin-AEYLR showed high affinity for human EGFR and non-small-cell lung tumors.
- AEYLR peptide-conjugated nanostructured lipid carriers enhanced specific cellular uptake in EGFR-high tumor cells.
- The AEYLR peptide did not significantly inhibit or stimulate cell growth.
Conclusions:
- The AEYLR peptide exhibits potent EGFR-targeting capabilities.
- AEYLR serves as a potential safe and efficient delivery ligand for targeted cancer therapies, including chemotherapy, radiotherapy, and gene therapy.
- EGFR-mediated delivery using AEYLR holds promise for improving cancer treatment efficacy.
